Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #9 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Aurobindo Pharma Limited (this stock) | 96,203 | 37.4 | 9.2% | 54.0% | — | 83 | 54 | 50 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 9,150 | 1,517 | 1,032 | ₹ |
| March 31, 2026 | 8,853 | 1,293 | 921 | ₹ |
| Dec. 31, 2025 | 8,646 | 1,338 | 910 | ₹ |
| Sept. 30, 2025 | 8,286 | 1,274 | 848 | ₹ |
| June 30, 2025 | 7,868 | 1,205 | 824 | ₹ |
| March 31, 2025 | 8,382 | 1,367 | 903 | ₹ |
| Dec. 31, 2024 | 7,979 | 1,198 | 846 | ₹ |
| Sept. 30, 2024 | 7,796 | 1,207 | 817 | ₹ |
| June 30, 2024 | 7,567 | 1,325 | 918 | ₹ |
| March 31, 2024 | 7,580 | 1,243 | 907 | ₹ |
| Dec. 31, 2023 | 7,352 | 1,265 | 940 | ₹ |
| Sept. 30, 2023 | 7,219 | 1,075 | 752 | ₹ |
| June 30, 2023 | 6,851 | 815 | 570 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 33,653 | 5,110 | 3,503 |
| March 31, 2025 | 31,724 | 5,098 | 3,484 |
| March 31, 2024 | 29,002 | 4,397 | 3,169 |
| March 31, 2023 | 24,855 | 2,624 | 1,928 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 5,526 | -3,458 | -1,269 | 2,686 | 2,841 |
| March 31, 2025 | 3,925 | -1,875 | 120 | 1,968 | 1,957 |
| March 31, 2024 | 2,435 | -4,256 | 800 | 2,780 | -346 |
| March 31, 2023 | 2,387 | -3,978 | 1,814 | 2,404 | -17 |
| March 31, 2022 | 5,016 | -3,215 | -2,969 | 2,053 | 2,964 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 58,502 | 37,883 | 37,833 | 6,873 | 803 | 32,709 | 18,039 | 7,191 | 14,330 | 12,053 |
| March 31, 2025 | 49,785 | 32,647 | 32,595 | 6,380 | 1,562 | 27,162 | 14,682 | 5,569 | 12,189 | 10,544 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
